RNA-seq in subcutaneous tumor tissue of RM1 from male Wild type and Plau-/- C57BL/6 mouse

This study aims to investigate the differential anti-tumor immune responses and transcriptomic profiles between wild-type (WT) and urokinase-type plasminogen activator knockout (uPA-/-) mice in the context of prostate cancer progression and therapy. By establishing a subcutaneous RM-1 tumor model in C57BL/6J mice, we seek to elucidate the role of uPA deficiency in modulating tumor microenvironment dynamics, particularly about immune checkpoint blockade responses. The research holds significant translational relevance as it may identify novel mechanisms by which plasminogen activation systems influence immunotherapy efficacy, potentially offering new biomarkers for patient stratification or therapeutic targets for prostate cancer treatment.